OPHTHETIC
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Jan 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 7h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPHTHETIC is an ophthalmic solution approved in 1961 for treatment of eye conditions via topical administration. The exact mechanism of action and specific indications are not publicly disclosed in available data. This is a legacy small-molecule product with a long commercial history.
LOE Approaching
Product approaching loss of exclusivity with low linked job openings, indicating a mature, smaller team or potential rightsizing phase.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
OPHTHETIC represents a legacy product with minimal active hiring and limited career growth trajectory. Working on this product would focus on defending market share, managing LOE transition, and potentially transitioning to generic formulations rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on OPHTHETIC at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.